|MDACC Study No:||2011-0016 (clinicaltrials.gov NCT No: NCT01369498)|
|Title:||A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Patients with Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis|
|Principal Investigator:||Srdan Verstovsek|
|Study Description:||The goal of this clinical research study is to compare the effectiveness and |
safety of GS-6624 at different dose levels with ruxolitinib in patients with
GS-6624 is a drug that is designed to bind to certain proteins. This may
prevent or slow the growth of cancer cells.
Ruxolitinib is designed to block a gene mutation that may be important in
cancer cell growth and survival. Ruxolitinib is the standard of care drug.